Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros

“Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros”, E. LOUIS (Department of Gastroenterology, University and CHU Liège, Liège, Belgium), Inflamm. Intest. Dis. 2022;7:64–68 (DOI: 10.1159/000520942). For more information: BIOCYCLE website: biocycle-project.eu EU reference: grant agreement No 633168 – BIOCYCLE (PHC-13-2014). 10. Stopping Anti-TNF in CD PRO

Presentation JFHOD2022

Arret de l’infliximab ou de l’antimétabolite dans la maladie de Crohn en rémission soutenue sans corticoide sous traitement combiné par infliximab et antimétabolite : essai randomisé controlé de décroissance thérapeutique SPARE », JFHOD2022 – established in the context of Dissemination portfolio 2022 of the BIOCYCLE project. For more information: BIOCYCLE website: biocycle-project.eu EU reference: grant agreement No…

Oral presentations ECCO 2022

Scientific session 1 : developing environmental recipes for IBD », Journal of Crohn’s and Colitis, 2022 – established in the context of Dissemination portfolio 2022 of the BIOCYCLE project. For more information: BIOCYCLE website: biocycle-project.eu EU reference: grant agreement No 633168 – BIOCYCLE (PHC-13-2014) Click here spare ECCO 2022

NEWS FROM BIOCYCLE

ECCO, a partner of the BIOCYCLE project, has dedicated pages 16 to 17 of its ECCO News Volume 12, Issue 2, 2017 to the BIOCYCLE project, providing information on BIOCYCLE progresses (ECCO News). The BIOCYCLE project has now been ongoing for almost 2 years. This project, funded by the European Commission under the Horizon 2020…

BIOCYCLE is hiring a DATA MANAGER

Background: The European Project – BIOCYCLE (https://www.biocycle.eu), project aims at assessing long-term treatment strategies in Crohn’s disease that will improve both safety and related costs while ensuring a constant level of eficacy during maintenance therapy. In that frame, IBDIM (research department of « European Crohn’s disease and Colitis Organization » – ECCO), one of the partners, is…